Applying New Data to Treatment Selection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A panel of experts discusses newly presented data from ASCO 2022 and how it affects potential treatment approaches for relapsed/refractory DLBCL.

EP. 1: A Focus on Frontline Treatment in Patients With DLBCL

June 30th 2022

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

EP. 2: Improving Outcomes in Patients With DLBCL

June 30th 2022

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

EP. 3: Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

EP. 4: Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

EP. 5: Comparing Real-World Evidence With Data From Clinical Trials

July 18th 2022

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

EP. 6: A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape

July 18th 2022

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

EP. 7: Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

July 22nd 2022

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

EP. 8: Therapeutic Sequencing and Bridging in DLBCL

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

EP. 9: Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

EP. 10: A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

EP. 11: Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

EP. 12: Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

EP. 13: The Future of DLBCL Treatment

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

EP. 14: Role of Bispecifics and Future Promising Treatments in DLBCL

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.